Lactate dehydrogenase, usually called LDH, is an enzyme found in nearly every cell in your body, and when a blood test shows elevated levels, it signals that cells somewhere are being damaged or are turning over faster than normal. In cancer care, LDH serves as a broad prognostic marker rather than a diagnostic one: it does not tell your doctor which cancer you have, but a high reading often means a tumor is growing aggressively, and it can help predict how well treatment will work. The distinction between “prognostic” and “diagnostic” matters here, because it shapes almost everything about how oncologists actually use the test.
Why Cancer Raises LDH
LDH is an enzyme that helps convert one molecule (pyruvate) into another (lactate) during the process your cells use to generate energy from glucose. It sits inside cells and normally stays there. When cells are damaged or die, their contents spill into the bloodstream, and LDH levels rise.1Endocrine, Metabolic & Immune Disorders-Drug Targets. The Biochemical and Clinical Perspectives of Lactate Dehydrogenase: An Enzyme of Active Metabolism That is why a high LDH reading can show up with liver disease, heart attacks, severe infections, or even intense exercise. It is not cancer-specific.
Cancer cells, however, have a particular reason for pumping out LDH. Most of your cells generate energy efficiently through oxygen-dependent pathways. Tumor cells tend to rely heavily on a less efficient, oxygen-independent process called aerobic glycolysis, even when oxygen is available. This quirk, identified decades ago and known as the Warburg effect, means cancer cells chew through glucose at a much higher rate and produce large amounts of lactate as a byproduct.2PubMed Central. Revisiting the Warburg Effect with Focus on Lactate The enzyme responsible for that last conversion step is LDH. So tumors both overexpress the enzyme and, through rapid cell turnover and death, release it into the blood. The result is often a measurably elevated serum LDH.
In some cancers, the shift toward this metabolic strategy is driven by specific genetic changes. In prostate cancer, for example, certain growth-factor signaling pathways actively reprogram which forms of LDH a cell produces, pushing metabolism further toward glycolysis.3Cancer Research. Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer The upshot is that a rising LDH in a cancer patient often reflects both the tumor’s size and its metabolic aggressiveness.
Where LDH Shows Up in Cancer Staging and Prognosis
LDH is not equally useful across every cancer type. Its role is best established in melanoma, certain lymphomas, germ cell tumors, and some pediatric cancers. In other solid tumors it is used more informally, as one data point among many.
Melanoma is the cancer where LDH has been most formally incorporated into staging. The American Joint Committee on Cancer includes serum LDH in its criteria for stage IV melanoma. Research backs this up: a large analysis of stage IV melanoma patients found that as LDH climbed, so did the risk of death, in a dose-response pattern. Patients whose LDH exceeded ten times the upper limit of normal faced dramatically worse outcomes compared to those with mildly elevated levels.4PubMed. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability Separately, a meta-analysis of melanoma patients receiving modern immunotherapy drugs found that those with elevated LDH before treatment had roughly two and a half times the risk of dying compared to patients with normal levels.5PubMed Central. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: a meta-analysis
In testicular germ cell tumors, LDH is one of three serum markers (alongside alpha-fetoprotein and human chorionic gonadotropin) that oncologists use routinely for diagnosis, staging, tracking treatment response, and long-term surveillance.6PubMed Central. Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance It is particularly useful in seminomas, where the other two markers are less reliably elevated.
In blood cancers such as diffuse large B-cell lymphoma, serum LDH functions as a surrogate for tumor burden. Studies have found it to be an independent predictor of survival, and it is built into the International Prognostic Index that doctors use to classify how aggressive a lymphoma appears at diagnosis.7Cellular Physiology and Biochemistry. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma Similarly, in extranodal NK/T-cell lymphoma, elevated LDH at initial diagnosis points toward a worse prognosis.8PubMed Central. The prognostic value of lactate dehydrogenase/albumin ratio in extranodal natural killer/T cell lymphoma
LDH in Pediatric Cancers
LDH carries particular weight in neuroblastoma, one of the most common childhood cancers. An international study involving thousands of children found a clear, tiered relationship between LDH levels and survival. Children with the highest LDH readings at diagnosis had roughly half the five-year event-free survival of those with moderate levels. Even after accounting for other known risk factors like age and genetic amplification of the MYCN gene, LDH remained an independent predictor of outcomes.9PubMed. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project Pediatric oncologists often use LDH alongside other markers to decide how aggressively to treat.
Tracking Treatment Response
Beyond prognosis at diagnosis, LDH has growing value as a real-time monitoring tool. If a tumor responds to chemotherapy, its cells stop dividing and dying at such a rapid clip, and LDH should drift downward. If the tumor is not responding or the disease is progressing, LDH tends to climb. In nasopharyngeal carcinoma, researchers found that tracking the ratio of LDH from one scan to the next was a useful predictor of whether the tumor was growing or shrinking. An LDH ratio above 1.0 between consecutive treatment cycles predicted disease progression with moderate accuracy.10PubMed Central. Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma
In breast cancer, elevated LDH has been linked to metastasis and disease recurrence, giving clinicians an early warning flag even before imaging might catch a change.11Biomedicine & Pharmacotherapy. Lactate Dehydrogenase and Biochemical Markers as Indicators of Treatment Response in Breast Cancer The general principle is the same across tumor types: trending LDH over time adds a layer of information that a single snapshot cannot provide.
Why LDH Matters for Immunotherapy
The connection between LDH and immunotherapy response deserves its own discussion because the mechanism goes beyond simple tumor burden. Lactate, the product of the reaction LDH catalyzes, accumulates in the space surrounding a tumor. That acidic, lactate-rich environment actively suppresses the immune cells that need to attack the cancer. Specifically, high lactate levels inhibit killer T cells and natural killer cells while supporting immune-suppressive cell populations.12PubMed Central. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives Lactate can also reprogram macrophages, dendritic cells, and other immune cells toward states that tolerate the tumor rather than fight it.13PubMed Central. Roles of lactate and lactylation in tumor immune suppression and drug resistance
This means high LDH is not just a bystander reading in patients starting immunotherapy; it reflects a biological reality that makes the drugs less effective. In advanced melanoma treated with the combination of ipilimumab and nivolumab, patients whose LDH was normal had an objective response rate around 65%, while those with LDH more than double the upper limit of normal saw that rate drop to roughly 38%. Four-year survival told a similar story: about 61% for patients with normal LDH compared to 28% for those with the highest levels.14PubMed Central. Lactate dehydrogenase: a marker of diminished antitumor immunity In advanced non-small cell lung cancer, a meta-analysis found that elevated pretreatment LDH roughly doubled the risk of death in patients receiving immune checkpoint inhibitors.15PubMed Central. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
The finding is consistent enough that some oncologists consider LDH when weighing whether to recommend immunotherapy, chemotherapy, or a combination. A very high LDH might prompt a more aggressive upfront approach or closer monitoring early in treatment.
What LDH Cannot Tell You
For all its usefulness, LDH has fundamental limitations that are easy to overlook. The biggest one is that it is nonspecific. A high LDH can come from a heart attack, a bad case of pneumonia, a blood disorder, liver disease, or even a strenuous workout. It does not point to cancer on its own, and it cannot identify a cancer type. This is why LDH is never used as a screening tool for cancer in healthy people. Its value only emerges once a cancer diagnosis is established or strongly suspected.
Even within cancer care, LDH by itself has limited specificity. A patient with metastatic melanoma and an elevated LDH might have that elevation driven partly by liver metastases damaging liver tissue rather than by the tumor’s own metabolic activity. Both mechanisms raise LDH, but they carry different implications for treatment planning. Doctors interpret LDH alongside imaging, other blood markers, and clinical context, never in isolation.
False Elevations and Lab Pitfalls
LDH testing is also vulnerable to preanalytical errors, meaning things that go wrong before the lab even runs the assay. The most common culprit is hemolysis: if red blood cells break open during blood collection or handling, they spill their LDH into the sample and artificially inflate the reading. Because red blood cells are packed with LDH, even modest hemolysis can push a result above the reference range. A key challenge for labs is distinguishing whether hemolysis happened inside the patient’s body (which could be clinically meaningful) or inside the collection tube (which is just an artifact).16PubMed. Adjustment of lactate dehydrogenase concentration results according to the haemolysis index following in vitro haemolysis
Another less obvious source of false elevation is pneumatic tube systems, the pressurized tubes hospitals use to shoot blood samples from patient floors to the lab. The acceleration forces inside these tubes can damage cells in the sample. One study found that plasma LDH values were 26% to 149% higher after transport through a pneumatic tube system compared to hand-delivered samples, even when there was no visible hemolysis.17PubMed. Falsely Increased Plasma Lactate Dehydrogenase without Hemolysis Following Transport through Pneumatic Tube System Many hospitals have now studied their own tube systems and in some cases require hand delivery for LDH-sensitive specimens.18PubMed. Evaluating accelerations across multiple routes of a pneumatic tube system to ensure sample integrity for LDH measurement
If your LDH result seems unexpectedly high and your doctor is puzzled, a redraw with careful handling is a reasonable step before making clinical decisions based on it.
LDH Beyond Blood Tests
Serum LDH gets most of the attention, but the enzyme is also measured in body fluids like pleural fluid, the liquid that can accumulate around the lungs. When a patient develops a pleural effusion, one of the first clinical questions is whether it is caused by something local (an exudative effusion, often from infection or cancer) or by a systemic condition like heart failure (a transudative effusion). The ratio of LDH in the pleural fluid to LDH in the blood is one of the standard criteria doctors use to make this distinction, alongside protein ratios.19PubMed Central. Pleural Fluid Biomarkers in Focus: The Role of Cholesterol and Lactate Dehydrogenase (LDH) in Differentiating Exudative From Transudative Effusions A high pleural-to-serum LDH ratio strongly suggests an exudative process, which then prompts further workup for infection, malignancy, or inflammatory disease.
The same general principle applies to cerebrospinal fluid, pericardial fluid, and ascitic fluid. LDH measured in these compartments can help distinguish benign from more worrisome causes of fluid accumulation.
LDH Isoenzymes and What They Add
Total LDH is what most standard blood panels measure, but the enzyme actually exists as five different isoforms (LDH-1 through LDH-5), each concentrated in different tissues. The heart and red blood cells are rich in LDH-1 and LDH-2, the liver and skeletal muscle in LDH-4 and LDH-5, and the lungs in LDH-3.20PubMed Central. Clinical and Diagnostic Significance of Lactate Dehydrogenase and Its Isoenzymes in Animals In theory, measuring which isoform is elevated could pinpoint where the damage is happening. Early work in the 1960s used this approach to identify heart attacks (LDH-1 elevation) and liver disease (LDH-5 elevation) based on the characteristic isoenzyme pattern each tissue leaves in the blood.21Nature. Origin of the Lactate Dehydrogenase Isoenzyme Pattern found in the Serum of Patients having Primary Muscular Dystrophy
In practice, isoenzyme fractionation has been largely overtaken by more specific modern tests. Troponin replaced LDH isoenzymes for diagnosing heart attacks years ago. For cancer, total LDH remains the standard order because most tumors elevate a mix of isoforms, and the added cost of fractionation rarely changes clinical decisions. Still, you may see isoenzyme panels ordered in ambiguous cases where a doctor wants to rule out a non-cancer source of an unexplained LDH elevation.
Efforts to Target LDH as Therapy
Because LDH sits at the center of tumor metabolism, researchers have wondered whether blocking the enzyme itself could starve cancer cells. Drug development in this area is still early-stage. One promising line of research identified a compound that inhibits LDH and shows anticancer activity across multiple cell lines in the lab, particularly when combined with drugs that block another part of the energy-production pathway.22PubMed. Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment The challenge is selectivity: LDH is everywhere in your body, so a drug that shuts it down indiscriminately could cause serious side effects in healthy tissues. None of these inhibitors have reached late-stage clinical trials yet, but the concept remains active in cancer metabolism research.
A parallel strategy focuses not on LDH itself but on the lactate it produces. Since tumor-derived lactate suppresses the immune system in the area around the cancer, some researchers are exploring whether neutralizing that lactate or blocking its transport could restore immune function and make immunotherapy more effective. This is a conceptually appealing idea, but translating it into a safe, effective drug is a long road.
How Doctors Typically Use the Test in Practice
If you are a cancer patient and your oncologist orders an LDH level, the test is almost always being used in one of a few specific ways. At diagnosis, it helps estimate how much cancer is present and how aggressively it is behaving. Before starting treatment, particularly immunotherapy, it contributes to the discussion about expected response. During treatment, serial LDH measurements can provide early signals that therapy is working or failing, sometimes before imaging catches up. And during surveillance after treatment ends, a rising LDH can be an early flag for recurrence.
What it does not do is screen for cancer in healthy people, identify a specific cancer type from a blank slate, or provide enough information on its own to change a treatment plan. A mildly elevated LDH in a routine blood panel, without any other signs or symptoms, is far more likely to reflect something benign than an occult malignancy. Your doctor would typically repeat the test, check for hemolysis or other lab artifacts, and consider non-cancer causes before pursuing an oncologic workup. LDH earns its keep in cancer care as a supporting player: cheap, widely available, easy to repeat, and genuinely informative when read alongside the rest of the clinical picture.